Potential biomarkers for immunotherapy in non-small-cell lung cancer

被引：13

作者：

Wang, Xing ^{[1
]}

Qiao, Ziyun ^{[1
]}

Aramini, Beatrice ^{[2
]}

Lin, Dong ^{[1
]}

Li, Xiaolong ^{[1
]}

Fan, Jiang ^{[1
]}

机构：

[1] Shanghai Gen Hosp, Dept Thorac Surg, Shanghai, Peoples R China

[2] Univ Bologna, GB Morgagni L Pierantoni Hosp, Dept Expt Diagnost & Specialty Med DIMES Alma Mate, Div Thorac Surg, Forli, Italy

来源：

CANCER AND METASTASIS REVIEWS | 2023年 / 42卷 / 03期

基金：

中国国家自然科学基金;

关键词：

Non-small-cell lung cancer; Immune checkpoint inhibitors; Biomarker; CIRCULATING TUMOR DNA; METASTATIC UROTHELIAL CARCINOMA; RESIDUAL DISEASE MRD; PD-L1; EXPRESSION; OPEN-LABEL; MUTATIONAL BURDEN; METHYLATION MARKERS; 1ST-LINE TREATMENT; PREDICTS RESPONSE; PROGNOSTIC VALUE;

D O I：

10.1007/s10555-022-10074-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

For individuals with advanced or metastatic non-small cell lung cancer (NSCLC), the primary treatment is platinum-based doublet chemotherapy. Immune checkpoint inhibitors (ICIs), primarily PD-1/PD-L1 and CTLA-4, have been found to be effective in patients with NSCLC who have no EGFR/ALK mutations. Furthermore, ICIs are considered a standard therapy. The quantity of fresh immunogenic antigens discovered by cytotoxic T cells was measured by PD-L1 expression and tumor mutational burden (TMB), which were the first biomarkers assessed in clinical trials. However, immunotherapy did not have response efficacy markers similar to targeted therapy, highlighting the significance of newly developed biomarkers. This investigation aims to review the research on immunotherapy for NSCLC, focusing primarily on the impact of biomarkers on efficacy prediction to determine whether biomarkers may be utilized to evaluate the effectiveness of immunotherapy.

引用

页码：661 / 675

页数：15

共 153 条

[1] Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection [J].

Abbosh, Christopher ;

Birkbak, Nicolai J. ;

Swanton, Charles .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (09) :577-586

[2] Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors [J].

Adalsteinsson, Viktor A. ;

Ha, Gavin ;

Freeman, Samuel S. ;

Choudhury, Atish D. ;

Stover, Daniel G. ;

Parsons, Heather A. ;

Gydush, Gregory ;

Reed, Sarah C. ;

Rotem, Denisse ;

Rhoades, Justin ;

Loginov, Denis ;

Livitz, Dimitri ;

Rosebrock, Daniel ;

Leshchiner, Ignaty ;

Kim, Jaegil ;

Stewart, Chip ;

Rosenberg, Mara ;

Francis, Joshua M. ;

Zhang, Cheng-Zhong ;

Cohen, Ofir ;

Oh, Coyin ;

Ding, Huiming ;

Polak, Paz ;

Lloyd, Max ;

Mahmud, Sairah ;

Helvie, Karla ;

Merrill, Margaret S. ;

Santiago, Rebecca A. ;

O'Connor, Edward P. ;

Jeong, Seong H. ;

Leeson, Rachel ;

Barry, Rachel M. ;

Kramkowski, Joseph F. ;

Zhang, Zhenwei ;

Polacek, Laura ;

Lohr, Jens G. ;

Schleicher, Molly ;

Lipscomb, Emily ;

Saltzman, Andrea ;

Oliver, Nelly M. ;

Marini, Lori ;

Waks, Adrienne G. ;

Harshman, Lauren C. ;

Tolaney, Sara M. ;

Van Allen, Eliezer M. ;

Winer, Eric P. ;

Lin, Nancy U. ;

Nakabayashi, Mari ;

Taplin, Mary-Ellen ;

Johannessen, Cory M. .

NATURE COMMUNICATIONS, 2017, 8

[3] TMB or not TMB as a biomarker: That is the question [J].

Addeo, Alfredo ;

Friedlaender, Alex ;

Banna, Giuseppe L. ;

Weiss, Glen J. .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 163

[4] Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy [J].

Althammer, Sonja ;

Tan, Tze Heng ;

Spitzmuller, Andreas ;

Rognoni, Lorenz ;

Wiestler, Tobias ;

Herz, Thomas ;

Widmaier, Moritz ;

Rebelatto, Marlon C. ;

Kaplon, Helene ;

Damotte, Diane ;

Alifano, Marco ;

Hammond, Scott A. ;

Dieu-Nosjean, Marie-Caroline ;

Ranade, Koustubh ;

Schmidt, Guenter ;

Higgs, Brandon W. ;

Steele, Keith E. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

[5] Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer [J].

Amatu, A. ;

Barault, L. ;

Moutinho, C. ;

Cassingena, A. ;

Bencardino, K. ;

Ghezzi, S. ;

Palmeri, L. ;

Bonazzina, E. ;

Tosi, F. ;

Ricotta, R. ;

Cipani, T. ;

Crivori, P. ;

Gatto, R. ;

Chirico, G. ;

Marrapese, G. ;

Truini, M. ;

Bardelli, A. ;

Esteller, M. ;

Di Nicolantonio, F. ;

Sartore-Bianchi, A. ;

Siena, S. .

ANNALS OF ONCOLOGY, 2016, 27 (06) :1062-1067

[6] Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer [J].

Anagnostou, Valsamo ;

Forde, Patrick M. ;

White, James R. ;

Niknafs, Noushin ;

Hruban, Carolyn ;

Naidoo, Jarushka ;

Marrone, Kristen ;

Sivakumar, I. K. Ashok ;

Bruhm, Daniel C. ;

Rosner, Samuel ;

Phallen, Jillian ;

Leal, Alessandro ;

Adleff, Vilmos ;

Smith, Kellie N. ;

Cottrell, Tricia R. ;

Rhymee, Lamia ;

Palsgrove, Doreen N. ;

Hann, Christine L. ;

Levy, Benjamin ;

Feliciano, Josephine ;

Georgiades, Christos ;

Verde, Franco ;

Illei, Peter ;

Li, Qing Kay ;

Gabrielson, Edward ;

Brock, Malcolm V. ;

Isbell, James M. ;

Sauter, Jennifer L. ;

Taube, Janis ;

Scharpf, Robert B. ;

Karchin, Rachel ;

Pardoll, Drew M. ;

Chaft, Jamie E. ;

Hellmann, Matthew D. ;

Brahmer, Julie R. ;

Velculescu, Victor E. .

CANCER RESEARCH, 2019, 79 (06) :1214-1225

[7] Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a UK multicenter prospective study (TRACC) [J].

Anandappa, Gayathri ;

Starling, Naureen ;

Begum, Ruwaida ;

Bryant, Annette ;

Sharma, Shruti ;

Renner, Derrick ;

Aresu, Maria ;

Peckitt, Clare ;

Sethi, Himanshu ;

Feber, Andrew ;

Potter, Vanessa Alice ;

Paraoan, Marius ;

Abulafi, Muti ;

George, Nicol ;

Branagan, Graham ;

Duff, Sarah ;

West, Nicholas ;

Aleshin, Alexey ;

Chau, Ian ;

Cunningham, David .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)

[8] Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients [J].

Anantharaman, Archana ;

Friedlander, Terence ;

Lu, David ;

Krupa, Rachel ;

Premasekharan, Gayatri ;

Hough, Jeffrey ;

Edwards, Matthew ;

Paz, Rosa ;

Lindquist, Karla ;

Graf, Ryon ;

Jendrisak, Adam ;

Louw, Jessica ;

Dugan, Lyndsey ;

Baird, Sarah ;

Wang, Yipeng ;

Dittamore, Ryan ;

Paris, Pamela L. .

BMC CANCER, 2016, 16

[9] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[10] Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer A Review [J].

Arbour, Kathryn C. ;

Riely, Gregory J. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (08) :764-774

← 1 2 3 4 5 6 7 8 9 10 →